GC Genome (A340450) Stock Overview
Operates as a clinical genome analysis company in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
A340450 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
GC Genome Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,850.00 |
| 52 Week High | ₩10,900.00 |
| 52 Week Low | ₩4,700.00 |
| Beta | 0 |
| 1 Month Change | -26.74% |
| 3 Month Change | -38.61% |
| 1 Year Change | -52.12% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -56.31% |
Recent News & Updates
Recent updates
Shareholder Returns
| A340450 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -9.0% | 3.3% | 15.6% |
| 1Y | -52.1% | 13.7% | 185.0% |
Return vs Industry: A340450 underperformed the KR Biotechs industry which returned 13.7% over the past year.
Return vs Market: A340450 underperformed the KR Market which returned 185% over the past year.
Price Volatility
| A340450 volatility | |
|---|---|
| A340450 Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in KR Market | 16.1% |
| 10% least volatile stocks in KR Market | 4.5% |
Stable Share Price: A340450 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A340450's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | Chang-Seok Ki | www.gcgenome.com |
GC Genome Corporation operates as a clinical genome analysis company in South Korea. It offers hereditary cancer, tissue and liquid biopsy genetic, blood cancer, and homologous recombination deficiency tests under the Green Plan names; Guardant360, a blood genetic profiling test; Guardant Reveal, a liquid biopsy microscopic residual disease detection and recurrence monitoring test; and genetic rare disease testing services for chromosomal microarray, targeted exome sequencing, whole exome sequencing, and diagnostic genome sequencing. The company also provides ai-CANCERCH, an AI algorithm-based multi-cancer early screening test; Jins Sketch, a genetic test for personalized nutrition; Genome Health and Risk Screen that identifies various disease-susceptibility genes; Green Biome for human symbiotic microorganism genetic analysis service; Genome Screen, an optimal genetic test for preemptive action; Telorisk, an indicator of biological age; and drug compatibility DNA test.
GC Genome Corporation Fundamentals Summary
| A340450 fundamental statistics | |
|---|---|
| Market cap | ₩114.71b |
| Earnings (TTM) | ₩4.56b |
| Revenue (TTM) | ₩32.16b |
Is A340450 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A340450 income statement (TTM) | |
|---|---|
| Revenue | ₩32.16b |
| Cost of Revenue | ₩17.16b |
| Gross Profit | ₩14.99b |
| Other Expenses | ₩10.43b |
| Earnings | ₩4.56b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 192.86 |
| Gross Margin | 46.62% |
| Net Profit Margin | 14.18% |
| Debt/Equity Ratio | 0% |
How did A340450 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/19 21:25 |
| End of Day Share Price | 2026/06/19 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
GC Genome Corporation is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Eui-Seob Shim | NH Investment & Securities Co., Ltd. |